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Despite the expression of Fas, some clones of myeloma 
cells are resistant to Fas-mediated apoptosis. To define a 
cellular factor involved in the resistance, we performed 
a comparative study using two clones of myeloma cells, 
RPMI8226 and U266. These cells were reported to 
express cell surface Fas at similar levels, but only 
RPMI8226 cells lost their viability upon anti-Fas treat-
ment. The resistance of U266 cells to anti-Fas did not 
appear to reflect dysregulation of BcI-2, BcI-XL' and Bax, 
because these proteins were expressed in both RPMI8226 
and U266 cells to similar levels. Moreover, levels of 
those proteins were not significantly altered by treating 
RPMI8226 cells with IL-6, a cytokine which suppresses 
the Fas-mediated death of RPMI8226 cells. Interestingly, 
mRNA levels of FLIPL, an endogenous inhibitor of 
Fas signaling, were constitutively elevated in U266 cells. 
Consistent with this observation, U266 cells expressed 
both FLIPL protein and its truncated 43 kDa product 
which is seen in FLIPL-overexpressing cells. The trun-
cated form of FLIPL protein was not detected in 
RPMI8226. Moreover, the levels of truncated FLIP L 
in U266 cells were considerably higher than those of 
pro-FLlPL in RPMI8226. The overall data indicate that 
FLlPL is constitutively hyperexpressed in U266 cells. 
However, IL-6 failed to enhance the protein levels of 
FLIP molecules in either of the tested cells. It appears, 
therefore, that FLIPL plays a role in the intrinsic 
resistance of U266 cells to the apoptotic action of Fas, 
but is not involved in the protective action of IL-6. 
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Introduction 
Multiple myeloma is a B cell malignancy resulting from 
the uncont rolled expansion of a single clone of plasma 
cells (myeloma cell s) in the bone marrow. Although 
this outgrowth of neoplastic clones reflects either their 
enhanced capacity to proliferate or a decreased rate 
of cell death (apoptosis), this la tter mechanism may be 
particularly important in slowly proliferating tumors 
such as multiple myeloma . Indeed , many, but not all , 
clones of myeloma cells can withstand a lethal stimulus 
such as an agonistic anti-Fas antibody (anti -Fas) 
(Shima el al., 1995; 1996; Westendorf, el al. , 1995). 
Moreover, when the cell s are exposed to IL-6, the Fas-
mediated death of other susceptible clones is suppressed 
(Chauhan el al., 1997; Shima el al. , 1995; Xu el al. , 
1998). To date, however, the mechanisms underlying the 
intrinsic and IL-6-induced ability of myeloma cell s to 
survi ve against anti-Fas have been poorly described. 
Fas (APO-I /CD95) is a member of the TNF/nerve 
growth factor receptor family , and is expressed in a wide 
variety of normal and transformed cells (ltoh el al. , 
199 1). Upon binding to its ligand, Fas rapidly under-
goes oligomerization, followed by recruitment of an 
adapto r molecule FADD/MORTI to the ligated recep-
tor (Chinnaiyan el al., 1996). FADD, in turn, associates 
with caspase-8 (FLICE/MACH/MCH5) through death 
effector domains (DEDs) present at the C-terminus of 
FADD and the N-terminus of caspase-8, forming the 
death-inducing signaling complex (DISC) (Boldin e/ al. , 
1996). Recruitment of caspase-8 to the DISC leads to 
its proteolytic activation, which then triggers a down-
stream signaling cascade that culminates in apoptosis 
(Ashkennazi and Dixit, 1998) . 
FLIP (FLAME-l /MRIT/CLA RP) is a recently 
identified cellular protein which can interfere with the 
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Fas-induced activation of caspase-8 (Irmler et aI. , 1997; 
Srinivasula el al., 1997). Human cells express two 
alternat ively spliced isofo rms of FLIP, FLIPs (28 kDa) 
and FLIPL (55 kDa) (Irmler et al. , 1997). They both 
co ntain two DEDs, which a re, in the case of FLIP L, 
followed by a caspase-Iike domain at the C-terminus. 
Nevertheless, FUPL is believed to be catalytically 
inactive because the acti ve-center cystei ne residue is 
subst ituted by a tyrosine residue. FLIPs and FUPL can 
interact with FADD and caspase-8 through D EDs, 
resulting in blockage of the caspase-8 activation at the 
DISC. Co nseq uent ly, cells stably overexpressing FLIP 
molecules have been shown to resist Fas-mediated 
apoptosis (Scaffidi et al., 1999). 
Based on the inhibitory role of FLIP, it seems 
possible that the cellula r level of FLIP may be a factor 
influenci ng the suscept ibility/ resistance of myeloma cells 
to Fas-mediated apoptosis . To address this question , 
we performed a comparative study using two clones of 
mye loma cells, RPMI8226 and U266, which have been 
shown to express Fas to similar levels (Shima et al., 
1996). In contrast to RPMI 8226 which undergoes death 
upon Fas ligat ion (Shima el al. , 1995), U266 cells a re 
resistant to anti-Fas trea tment. Interestingly, the FLIPL 
protein was found to be hyperexpressed in U266 cells. 
However, lL-6 failed to eleva te the protein levels of 
either FUPL or FLIPs in RPM18226 cells. Therefore, 
FUPL appea rs to playa role in the intrinsic resistance 
of U266 cell s to Fas-mediated apop tosis, but does not 
appea r to be involved in the protective action of IL-6. 
Materials and Methods 
Materia ls The culture medium and its supp lements were 
purchased from Bio Wilitta ker (Walkersvil le, MD). All the 
antibod ies were ra ised aga inst human proteins, and were 
purchased from the following so urces; anti-FLIP and -Bax , 
Pharmingen (Sa n Diego, CA); anti-BcI-2, DAKO (Carpinte-
ri a, CA); a nti -Bcl-X L , Transd uction La bora tories (Lexington, 
K Y); anti-Fas (IgM) , Upstate Biotechn ology (Lake Placid , 
Y) . Promega (Mad ison , WI) provided deoxynucleotide 
triphosphate (dNTP), RNasin , avian myeloblastosis virus 
reverse transcriptase, and rand om hexamer. 
Cell cul ture and treatments RPMl8226 and U266 cells were 
cu ltured in RPMII640 medium supplemented with 10% heat-
inact iva ted FBS and gentamicin (50 ~lg/ml). To treat cells with 
ant i-Fas and IL-6, the cell density was adjusted to 3 x I05/ml. 
The untreated control and treated cells were maintained at 
37°C in 5% CO2 and high humidi ty for the periods of time 
indicated. 
Analysis of viability Incubated cells received propidum iodide 
(PI) (5 ~lg/ml) , followed by analysis on a FACScan flow 
cytometer (Becton Dichinson, Mounta in View, CA) to simul-
taneously monitor PI uptake (FL-2 channel) and cell size 
(forward light scatter) . The cells that displayed both a reduction 
in cell size and a high permeability to PI were understood to be 
dead , as previously defined (Ma nga n el at., 1991 ). 
Western blotting Cell Iysates were prepared as described 
previous ly (Lee and Um, 1999). Equal amounts of proteins 
(25- 100 flg) were separated by SDS-PAGE, then electrotrans-
fe rred to lmmobilon membranes (M ill ipore, Bedford , MA) 
wh ich were subseq uently blo tted using the indicated antibod-
ies and visua lized by chemiluminescence (ECL; Amersham, 
Arlington Heights, IL). 
RT-PCR analysis Tota l RNA from indicated cells was 
extracted using Tri-reagent (Sigma, St. Loui s, MO). First-
strand cDNA was synthesized at 37°C for I h in 50 ~t1 of 
reacti on mi xture conta ining 3 ~lg of tota l RNA, 1.5 mM of 
each dNTP, 0.5 flg of random hexamer, 10 units of avian 
myelob lastosis virus reverse transcriptase, and 25 units of 
RN asin . PC R reactions were then performed in a total volume 
of 25 ~t1 containing 5 pi of the transcribed cDNA , I unit of 
Taq DNA polymerase (Takara, Shiga, Japan), 0.2 flM of each 
d TP, 0.5 pCi of [o:32Pl-CTP, and 25 pmole of each primer. 
Two sets of primers were used for the amplification of FLIP 
cDNA; one (5'-ATG TCT GCT GAA GTC ATC CAT C-3', 
and 5'-TGC TCC TTG AAC AGA CTG C-3') specific to the 
N-terminal region of FLIP which is commonl y sha red by 
FLIPL and FLIPs, and the other (5'-TCA GAG CAT ACC 
TGA AGA G-3', and 5'-AGA GTG TGC TGC AGC CAG 
AC-3') specific to the C-terminal extension of FLIPL . For an 
interna l control, ~-actin cDNA was amplified by using 
5'-GTG GGG CGC CCC AGG CAC CA-3' and 5'-TCC 
TTA ATG TCA CGC ACG ATT TC-3' . The optimal number 
of cycles for RT-PCR was determined as previously described 
(Becker el at. , 1991 ), and we performed the ampbfication at 23 
cycles for ~-actin, a t 25 cycles for the shared N-termina l region 
of F LIP, and a t 27 cycles for the C-terminal ex tension of 
FUPL . Each cycle included dena tura tion a t 94°C for 30 s, 
primer annealing at 60°C for 30 s, and extension at n oc for 
I min . Ten ~t1 of the reaction mixture was separated on 5% 
acrylamide gels, and the rela tive levels of amplification were 
compared by a utoradiography of the gels. 
Results 
Anti-Fas ki lls RPMI8226, but not U266 myeloma 
cells RPMI8226 myeloma cells express Fas on their 
surface, and thus undergo death upon exposure to anti-
Fas (Shima el al., 1995). The cell death was suppressed 
by the addition of IL-6 (Fig. I) , as reported previously 
(Shima el al., 1995) . It has also been reported that U266 
clones of myeloma cells express cell surface F as to a 
level similar to that observed in RPMI8226 cells (Shima 
el aI. , 1996). However, U266 cells resisted the anti-Fas 
treatment even in the absence of exogenous IL-6 
(Fig. I) . These data suggested that U266 cells constit-
utively express an anti-death protein(s) which blocks the 
Fas signaling. 
BeI-2, Bel-XL' and Bax are not hyperexpressed in U266 
cells Bcl-2 and Bcl-XL are well characterized anti-death 
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proteins. Gi ven tha t overexpression of either BcI-2 or 
BcI-X l ca n suppress Fas-media ted apoptosis (Scaffidi 
el al. , 1998) , we explored whether these protecti ve 
proteins were hyperexpressed in U266 cell s. However, 
levels of BcI-2 and BcI-Xl in U266 cell s were not higher 
than th ose in RPMI8226 (Fig. 2). It has been proposed 
tha t cellula r viability ca n be determined by the ra tio 
of BcI-2/Bax (Oltvai el al. , 1993). However, both 
RPMI 8226 and U266 cell s expressed Bax to simila r 
levels. It appeared, therefore, tha t the resistance of U266 
cell s to a nti-Fas did not result fro m dysregula tion of 
the tested members of the BcI-2 family. Moreover, the 
exposure of either RPMJ8226 or U266 cell s to IL-6 did 
not significantly alter their levels of BcI-2, BcI-Xl ' and 
Bax . 
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Fig. I. Differential responses of RPM[8226 and U266 cells to 
anti-Fas. RPMl8226 and U266 cells were incubated in the 
fo llowing conditions: circle, RPM [8226 in the absence of anti-
Fas and IL-6; square, RPMl8226 in the presence of anti-Fas 
(0.1 ~lg/ml) ; triangle, RPMl8226 in the presence of both anti-Fas 
and IL-6 (1,000 U /ml); diamond, U266 in the presence of anti-
Fas. Following the incubation times indicated, cellular viability 
was determined by fl ow cytometric analysis. The data is repre-
sentative of three similar experiments. The viability of untreated 
U266 cells was almost equal to those treated with anti-Fas. 
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Fig. 2. Expression of BcI-2, BcI-XL' and Bax. RPMI 8226 and 
U266 cells were incubated in the absence or presence of IL-6 
(1,000 U/ml) for 24 h. Levels of Bcl-2, Bcl-XL, and Bax were 
compared by Western blotting as described in Materials and 
Methods. 
FLIP is hyperexpressed in U266 cells Based on the 
report that Fas-mediated apoptosis is blocked by 
overexpression of FLIP (Irmler el al., 1997; Scaffidi 
el aI, 1999; Srinivasula el aI. , 1997), we next compa red 
the levels of FLIP molecules in RPMI8226 and U266 
ce lls. To do so, RT-PCR was co nducted by using a set 
of primers that was specific to the N-terminal region of 
both F LIPs and FLIPl mRNA. As shown in Fig. 3A, a 
grea ter amplifica tion was obta ined using cDNA from 
U266 cell s, suggesting higher levels o f FLIP mRNAs 
in the cells. Simila r results were obtained using the 
other set of primers that was specific to the C-terminal 
ex tension of FLIP l mRNA . Therefore, the FLIP 
mRNAs which were up-regula ted in U266 cell s involved 
FUPl mRNA. When levels of FLIP proteins were 
compared by Wes tern analysis, we did not detect the 
28 kDa FLIPs protein in either of the cells (Fig. 3B). 
While the two cells expressed the 55 kDa FUPl 
pro tein, the U266 cell s di splayed an additi onal protein 
ba nd corresponding to 43 kDa . This protein represents 
the proteolytica lly trunca ted fo rm of FLIPl protein , 
which has been commonly observed in cell s overex-
pressing FUPl (Irmler el al., 1997; Scaffifi et al. , 1999) . 
Importantly, the levels of the 43 kDa form in U266 cells 
were much higher than those of the 55 kDa form in 
RPMl8226 cells. These da ta suggested tha t expression 
of the FLlPl protein was enhanced in U266 cells to the 
(A) 
RPM! U266 
r-l r-l 
- + - + IL-6 
- - - --- FLlPL 
__ - - ~-actin 
(B) 
RPM! U266 
r-l r-l 
- + - + 
--
IL-6 
- 55kDa 
- 43kDa 
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Fig. 3. Expression of FLIP mRNA and proteins. RPMl8226 
and U266 were incubated in the absence or presence of TL-6 
(1,000 U/mI). A. At 8 h after the treatment, total RNA was 
ex tracted, and the levels of FUP mRNA were compared by RT-
PCR. B. After 24 h, the levels of FLIP proteins were analyzed by 
Western Blotting. 
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leve l tha t the protein co uld undergo its proteolytic 
cleava ge. 
IL-6 induces FLIP mR NA, but not its protein, in 
RPMI8226 cells To ex plo re whether the protecti ve 
effect of IL-6 is accompanied by the induct ion o f FUP, 
we trea ted RPMI8226 cell s wit h IL-6 for 8 h, a nd 
a na lyzed the levels of F UP mR A. As shown in 
F ig. 3A, IL-6 drama tica ll y en hanced the leve ls of FLIP 
mR A. Thi s effect of IL-6 wa obse rved using both sets 
of primers. However, IL-6 did not significa ntl y influence 
the level of the 55 kDa F UP l protein (F ig. 3B). 
M o reover, we did not detect a ny ind uctio n of the 
28 kDa F LIPs protein a nd the trunca ted form of FLlPl 
by trea ting RPMI 8226 ce ll s with IL-6. This was true 
when we a na lyzed the FLIP proteins from 4 h up to 
48 h afte r the treatment. These results indica ted that 
levels of F LI Pm RNA, but no t its protein , a re under the 
contro l o f IL-6 in RPMI 8226 cell s. 
I n the case of U266, levels of FLI P m RNA did not 
sign ifica ntl y respond to IL-6 (Fig. 3A), sugges ting that 
FLIP mR A was in a sa turated level with o ut the IL-6 
treatment. Similarly, the leve ls a nd expression pa tterns 
of FLIP proteins were no t a ltered by treat ing U266 cell s 
with IL-6 (F ig. 3B). 
Discussion 
Recent studies have demo nst rated that certa in clones o f 
mye loma cells resist Fas-mediated apoptosis (Shima 
el al., 1995; 1996; Westendorf, el al., 1995). To deter-
mine the cellula r facto r involved in the resistance , we 
have performed a compa ra ti ve stud y using RPMl8226 
a nd U266 myeloma cell s. A lthough these two ce ll s 
exp ress Fas to similar levels (Shima el al. 1996), o nl y 
RPM 18226, but not U266, cell s we re susceptible to the 
lethality by a nti-Fas . It a ppea rs tha t BcI-2 a nd BcI-X l 
are not the constitutive protectors o f U266 cells, beca use 
leve ls of those proteins were not enhanced in U266 cells , 
compa red to RPM18226 . Simila rl y, studies using differ-
ent se ts of myeloma cell s have repo rted tha t cellular 
levels of Bcl-2 and BcI-Xl a re not co-related to the 
respo nsiveness of myleoma cell s to a nti-Fas (Egle el al., 
1997). Although it has been proposed that the cellular 
level of Bax is a factor determining the susceptibility of 
certain clo nes of myeloma cell s to a nti-Fas (Egle el ai., 
1997) , we could not find such a co-relation using 
RPM 18226 a nd U266 cell s. Therefo re, the resistance 
to anti-Fas a ppea rs to be achieved by different mech-
a nisms depending on myelo ma cell clones. In the case of 
U266 cell s, we observed up-regulation o f FLIPl mRNA 
a nd its truncated form of protein . Although we cou ld 
not detect the FLIPs protein in the tested myeloma cells, 
this does not necessa rily indicate tha t the cell s do not 
express the FUPs mRNA. This argument is based on 
the obse rvat ion tha t huma n periphera l blood T ce ll s 
highl y express FUPs mRNA , but not its prote in ( Irm ler 
el al. , 1997) . Therefore, transcription of FLIPs does no t 
seem to a lways guarantee its tran slation, suggesting a 
contro l at the level of post-transcription. A lthough high 
levels of FLlP l pro tein were detected in ma lignant 
mela no ma ce ll s (lrmler el al. , 1997), thi s is, to o ur 
knowledge, the first report tha t FLI P can be dysregu-
la ted in myelo ma cells . The ro le of FLIP in apop tosis 
was initia ll y controversial: overex pression of FLIP 
resulted in either suppress io n o r promotion of Fas-
media ted cell death depending on experimental condi-
ti o ns (Ha n el al., 1997; I no ha ra el al. , 1997; Irmler 
el al. , 1997; Srinivasula el al. , 1997). It was later 
proposed that the promotion of cell death reflects the 
no n-phys iol ogica l functi o n o f FLIP in transient over-
expressio n systems, a nd tha t its sta ble hypexpress io n is 
a nti a poptotic (Scaffidi el al. , 1999). Mo reover, overex-
pression of FLlP l was shown to elic it a mo re potent 
protective effect than that o f FLIPs (Innler e l al., 1997). 
Interestingly, when FLlPl was overexpressed in BJAB 
lympho ma cells, only the 43 kDa , but not the 55 kDa, 
form of FUP l was detected in the DISC (Scaffifi el al. , 
1999). Thi s suggests tha t the 43 kDa form of FLlP l 
participates in the blockage o f Fas signaling. In thi s 
rega rd , the constitutive hyperex pressio n of the 43 kDa 
FLI P protein in U266 cell s is consistent with the 
intrinsic ability of the cells to survi ve aga inst a nti-Fas. 
Another importa nt findin g o f this stud y is tha t IL-6 
does no t regulate the levels of FLIP proteins in the 
tested myeloma cell s. A ltho ugh levels of FUP l mRNA 
in RPMl8226 ce ll s were enha nced by IL-6, thi s effect 
was not reflected in its protein level. This suggests tha t 
the expression of FLlP l , like FLIPs> can a lso be under 
post-transcriptiona l control. Certain cytokines such as 
TN FIX a nd I FN y were shown to elevate the mRNA 
levels of FLIP in microgli a l cell s (Spa na us el al., 1998). 
Based on our finding that the leve ls of FLIP mRNA a nd 
its protein can be differenti a ll y regulated , FLIP should 
be a na lyzed a t its protein level as well to confirm the 
actio n of the cytokines. We have also investiga ted 
the possibi lity that IL-6 could regula te cellu la r leve ls of 
Bcl-2, BcI-Xl' and Bax. However, we could not find 
evidence for this under o ur experimental conditions . 
Taken together, the da ta indica te tha t IL-6 can suppress 
the Fas-mediated dea th o f RPMI 8226 cells without 
a ltering the leve ls of FLI P proteins and the tested 
members of the BcI-2 family. C urrentl y, the mecha nism 
underl ying the protective action of IL-6 is unclea r. 
While IL-6 has been reported to suppress the Fas-
media ted activation o f stress-activated pro tein kinase/ 
c-Jun N-terminal kinase (SAPK/JNK) (Chauhan el al. , 
1997; Xu el al. , 1998) , whether SAPK acts as a mediator 
o f Fas-induced dea th in myeloma cell s remain s unan-
swered. Such a verificatio n a ppea rs to be important 
beca use the role of SAPK in Fas-mediated apoptosis 
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varies depending on the cell type (Ashkenazi and Dixit, 
1998). 
In summa ry, we have provided evidence that FLIP 
is dysregulated in F as-resistant U266 mye loma cell s. 
Therefo re, FLIP may be considered as a survival factor 
impa rting a t least those specific ce ll s with a n intrinsic 
res istance to letha lity by Fas ligation. Given tha t IL-6 
rescues Fas-sensitive RPMI8226 myeloma cell s without 
altering their leve ls o f FUP proteins, myeloma ce lls 
appear to have a n alternative control for their response 
to the Fas ligand. 
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